ARTICLE | Clinical News
Latuda regulatory update
February 3, 2017 12:01 AM UTC
FDA approved an sNDA from Sumitomo Dainippon’s Sunovion Pharmaceuticals Inc. subsidiary for Latuda lurasidone to treat schizophrenia in patients ages 13-17. Latuda is approved in the U.S. to treat adu...
BCIQ Company Profiles